Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasias de la mama - agentes antineoplásicos - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - inmunosupresores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

aurochem laboratories pvt. ltd. - tabletas recubiertas - 20 mg

Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

aurochem laboratories pvt. ltd. - tabletas - 500.00 mg

Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

aurochem laboratories pvt. ltd. - tabletas

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - metoxipolietilenglicol-epoetina beta - solucion inyectable - 100mcg/0.3ml - por ovulo - - metoxipolietilenglicol-epoetina beta

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - los sueros inmunes e inmunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ver secciones 4. 4 y 5.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

roche chile ltda. - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

roche chile ltda. - acido ascorbico - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

roche chile ltda. - acido ascorbico - sin formulas